Cells derived from iPSC can be immunogenic - yes or no?

Area of Science:

• Stem cell biology
• Immunology
• Regenerative medicine

Background:

• Induced pluripotent stem cells (iPSCs) are generated from somatic cells and hold promise for autologous cell therapies.
• Theoretically, iPSC-derived cells should be immune-tolerant, avoiding host rejection.
• Previous research indicates potential immunogenicity in syngeneic iPSC-derived cells, challenging this assumption.

Purpose of the Study:

• To investigate the immunogenicity of clinically relevant cells differentiated from human iPSCs.
• To address the need for rigorous immunogenicity testing before clinical translation of iPSC technology.

Main Methods:

• Utilized teratoma transplantation models.
• Differentiated iPSCs into various cell types and germ layers.
• Transplanted iPSC derivatives into syngeneic hosts for immunogenicity evaluation.

Main Results:

• Confirmed that certain iPSC-derived tissues can be immunogenic, even in syngeneic hosts.
• Findings align with recent studies suggesting immunogenicity in some iPSC derivatives, contrary to claims of "negligible" immunogenicity.
• Highlighted variability in immunogenicity across different iPSC-derived tissues.

Conclusions:

• iPSC-derived cells are not universally immune-tolerant.
• Further investigation into the immunogenicity of specific iPSC derivatives is crucial.
• Clinical translation of iPSC technology necessitates comprehensive immunogenicity assessment.